Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first- in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates: Mino-Lok® and LYMPHIR™. In May 2024, Citius announced positive topline results of Mino-Lok, its antibiotic lock solution to salvage catheters in patients with bloodstream infections. The Biologics License Application for LYMP ...